Savella patents expiration

Can you believe SAVELLA received compensation for the extended wait time during the regulatory approval process?
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US6602911 ALLERGAN Methods of treating fibromyalgia
Jan, 2023

(8 months ago)

US7994220 ALLERGAN Milnacipran for the long-term treatment of fibromyalgia syndrome
Sep, 2029

(5 years from now)

Savella is owned by Allergan.

Savella contains Milnacipran Hydrochloride.

Savella has a total of 2 drug patents out of which 1 drug patent has expired.

Expired drug patents of Savella are:

  • US6602911

Savella was authorised for market use on 14 January, 2009.

Savella is available in tablet;oral dosage forms.

Savella can be used as management of fibromyalgia (fm), management of fibromyalgia.

The generics of Savella are possible to be released after 19 September, 2029.

Drugs and Companies using MILNACIPRAN HYDROCHLORIDE ingredient

Market Authorisation Date: 14 January, 2009

Treatment: Management of fibromyalgia (fm); Management of fibromyalgia


How can I launch a generic of SAVELLA before it's drug patent expiration?
More Information on Dosage

SAVELLA family patents

Family Patents

900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight

Join them to stay ahead in capturing the next drug going generic